{
  "abstract": "Background and Importance Pre-exposure prophylaxis (PrEP) is an antiretroviral therapy containing emtricitabine and tenofovir disoproxil used to prevent HIV infection. It can be administered as continuous daily dosing or on-demand (event-driven).In 2023, the Italian Medicines Agency approved the reimbursement of PrEP by the National Health Service (NHS) for individuals at high risk of infection, based on a therapeutic plan prescribed by an infectious disease specialist.Aim and Objectives The study aims to analyse PrEP-related data and evaluate the economic impact of its provision through the NHS between November 2023 and April 2025.Material and Methods Data were extracted from the hospital information system and recorded by the pharmacy service.Results A total of 127 patients were included in the analysis, of whom three women and 124 men. Among them, 76% used PrEP on-demand, and 22% on a daily regime. At the time of the most recent dispensing age distribution was: 12% aged 18–28 years, 48% aged 29–40, 26% aged 41–48, and 15% aged 49 or older. Over the study period, 378 dispensing were recorded, with a minimum in February 2024 (1) and a maximum in January 2025 (39). Monthly public expenditure was also analysed, showing two peaks: a negative peak in February 2024 and a positive peak in January 2025, with an expenditure of €1,260. The total expense in the period is €7,419.Conclusion and Relevance Data analysis showed that most PrEP users were men aged 29–40 years, predominantly following an on-demand regimen. The number of dispensings showed an overall upward trend, with temporary declines in February and December 2024 due to temporary drug shortages. Pharmaceutical expenditure mirrored this pattern and was further affected by a supplier change that doubled the cost per package. The increasing use of PrEP indicates growing awareness and advancement in HIV prevention efforts.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy",
        "University of Cagliari, Specialisation School In Clinical Pharmacology and Toxicology, Cagliari, Italy"
      ],
      "name": "N Tatti"
    },
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy"
      ],
      "name": "M Rivano"
    },
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy"
      ],
      "name": "V Mureddu"
    },
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy"
      ],
      "name": "G Bertolino"
    },
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy"
      ],
      "name": "R Deidda"
    },
    {
      "affiliations": [
        "University Hospital Duilio Casula- Aou Cagliari, Pharmacy Hospital, Cagliari, Italy"
      ],
      "name": "A Cadeddu"
    }
  ],
  "title": "4CPS-167 Pre-exposure prophylaxis: socio-economic analysis",
  "uid": "779ac4ba-2ad4-57c6-a8a5-5f15c9254681"
}